Prescription patterns for antilipidemic drugs in a group of Colombian patients;Patrones de prescripción de antilipémicos en un grupo de pacientes colombianos

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 23, Issue 3, 2008, Pages 179-187

  Machado, Jorge Enrique ^a   Moncada, Juan Carlos ^b   Mesa, Giovanny ^b  

^a UNIVERSIDAD TECNOLÓGICA DE PEREIRA   (Colombia)

^b Audifarma SA ^*  (Colombia)

Author keywords

Colombia; Drug therapy; Drugs with prescription; Dyslipidemia; Hyperlipidemia; Hypertriglyceridemia; Lipid

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTIULCER AGENT;

CARDIOVASCULAR DISEASE; DISEASE TREATMENT; DRUG; LIPID; MORBIDITY; MORTALITY; RISK FACTOR; SOCIAL SECURITY;

ADULT; AGED; ARTICLE; COLOMBIA; COMPARATIVE STUDY; DRUG COMBINATION; DYSLIPIDEMIA; EVALUATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; PRESCRIPTION; STATISTICAL ANALYSIS; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTI-ULCER AGENTS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ASPIRIN; COLOMBIA; DATA INTERPRETATION, STATISTICAL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG;

COLOMBIA; SOUTH AMERICA;

EID: 44849120495     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bonita R, De Courten M, Dwyer T, Jamrozik K, Winkelmann R. Vigilancia de los factores de riesgo para enfermedades no transmisibles: el método progresivo de la OMS. Ginebra: Organización Mundial de la Salud; 2001.
2. Hobbs FD. Cardiovascular disease and lipids. Issues and evidence for the management of dyslipidaemia in primary care. Eur J Gen Pract. 2003;9(1):16-24.
3. Organización Panamericana de Salud. Resumen del Análisis de Situación y Tendencias de Salud. Colombia. Hallado en: URL:http:// www.paho.org/Spanish/SHA/prflCOL.htm. Acceso el 10 febrero 2006.
4. Cediel CV, Rodríguez RJ. Glicemia y perfil lipídico en un grupo de personas aparentemente sanas de la ciudad de Pereira. Rev Med Risaralda. 1995;1(1):3-6.
5. Caraballo GD, Grisales RH, Mazuera HM, Flórez GLE. Factores de riesgo para enfermedades cardiovasculares. Programa de prevención de la Universidad de Antioquia. Rev Fac Nac Salud Pública. 1997; 14(2):40-7.
6. Restrepo P, Ángel S. Identificación de factores de riesgo de enfermedad cardiovascular en pilotos aviadores comerciales en Santafé de Bogotá. Rev Col Cardiol. 2000;8(2): 108-14.
7. Montoya E, Navia J, Garzón M, Campos M, Orjuela A, Aycardi M, et al. Descripción de las características epidemiológicas en 1 000 pacientes con enfermedad coronaria. Rev Col Cardiol. 1997;6(2):203-7.
8. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and prevention of cardiovascular disease: summary of the 2003 update. CMAJ. 2003;169(9):921-4.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
10. Burchfiel C, Abbott R, Sharp D, Curb JD, Rodríguez B, Yano Y. Distribution and correlates of lipids and lipoproteins in elderly Japanese-American men. Arterioscler Thromb Vasc Biol. 1996;16:1356-64.
11. Pasternak RC. Report of the Adult Treatment Panel III: the 2001 National Cholesterol Education Program Guidelines on the Detection, Evaluation and Treatment of Elevated Cholesterol in Adults. Cardiol Clin. 2003;21(3):393-8.
12. Jones Freeman EL. Strategies for optimizing treatment outcomes. J Manag Care Pharm. 2003;9(1 Suppl):20-3.
13. Primatesta P, Poulter RN. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ. 2000;321:1322-5.
14. Brewer TN, Chapman BG, Brownlee S, Leventhal AE. Cholesterol control, medication adherence and illness cognition. Br J Health Psychol. 2002;7:433-47.
15. Sanal S, Aronow WS. Effect of an educational program on the prevalence of use of antiplatelet drugs, beta blockers, angiotensinconverting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers prescribed during hospitalization and at hospital discharge in patients with coronary artery disease. J Gerontol A Biol Sci Med Sci. 2003; 58(11):1046-8.
16. Delacrétaz E, Michalopoulos GP, Ruiz J, Saner H, Meier B. Management of hyperlipidaemia after coronary revascularisation: follow up study. BMJ. 1998;316:1499.
17. Colombia. Ministerio de Salud. Consejo Nacional de Seguridad Social en Salud. Acuerdo 228 de 2002. Diario Oficial. Hallado en: URL: http://www.minproteccionsocial.gov.co/
18. VBeContent/NewsDetail.asp?ID=14774&ID Company=3 Acceso el 31 mayo de 2006. 18. Colombia. Ministerio de Salud. Resolución 5061 de 1997. Diario Oficial. Hallado en: URL: http://www.minproteccionsocial.gov.co/ VBeContent/NewsDetail.asp?ID=14774&ID Company=3 Acceso el 31 mayo de 2006.
19. Isaza CA, Osorio FJ, Mesa G, Moncada JC. Patrones de uso de antihipertensivos en 11 947 pacientes colombianos. Biomédica. 2002; 22:476-85.
20. Colombia. Ministerio de Salud. Dirección de Desarrollo Científico y Tecnológico. Normas Científicas, Técnicas y Administrativas para la Investigación en Salud. Resolución No. 8430 de 1993. Diario Oficial. Hallado en: URL: http://www.minproteccionsocial.gov.co/ VBeContent/NewsDetail.asp?ID=14774&ID Company=3 Acceso el 31 mayo de 2006.
21. Davidson MH. Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care. 2006;12:S405-11.
22. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, et al.
23. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technolology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96:556-63.
24. Vasudevan AR, Jones PH. Effective use of combination lipid therapy. Curr Atheroscler Rep. 2006;8:76-84.
25. Hennekens CH. Update for primary healthcare providers: recent statin trials and revised National Cholesterol Education Program III guidelines. Med Gen Med. 2006; 8:54-9.
26. Eaton CB. Hyperlipidemia. Prim Care. 2005; 32:1027-55.
27. Quilliam BJ, Perez HE, Andros V, Jones P. Quantifying the effect of applying the NCEP ATP III criteria in a managed care population treated with statin therapy. J Manag Care Pharm. 2004;10:244-50.
28. Dalpino FB, Sodre FL, de FAria EC. The use of a hospital laboratory cohort to estimate the prevalence of dyslipidemia in an adult Brazilian population. Clin Chim Acta. 2006; 67:189-91.
29. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-67.
30. Mas J. Atherothrombosis: management of patients at risk. Int J Clin Pract 2005; 59:407-14.
31. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf. 2004;13:417-26.
32. Gómez J, Candás M, Fidalgo G, Armesto J, Calvo M, de Marino M, et al. Análisis del consumo de medicamentos utilizando indicadores de calidad en la prescripción. Aten Primaria. 2000;25:618-24.